Stock AQST AQUESTIVE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Aquestive Therapeutics, Inc.

Equities

AQST

US03843E1047

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
4.07 USD +3.56% Intraday chart for Aquestive Therapeutics, Inc. -0.85% +101.49%
Apr. 12 Aquestive Therapeutics, Inc. to Present Crossover Study Data for Libervant Buccal Film At 76th Annual Meeting of the American Academy of Neurology CI
Apr. 11 Piper Sandler Initiates Aquestive Therapeutics at Overweight With $10 Price Target MT

Business Summary

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. It is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. It has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.

Number of employees: 135

Sales per Business

USD in Million2022Weight2023Weight Delta
Pharmaceutical
100.0 %
48 100.0 % 51 100.0 % +6.09%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
73.4 %
40 83.7 % 37 73.4 % -7.06%
Ex-United States
26.6 %
8 16.3 % 13 26.6 % +73.72%

Managers

Managers TitleAgeSince
Daniel Barber CEO
 Chief Executive Officer 48 07-06-30
A. Toth DFI
 Director of Finance/CFO 65 20-12-30
Stephen Wargacki CTO
 Chief Tech/Sci/R&D Officer 46 14-12-31
Cassie Jung COO
 Chief Operating Officer 45 19-05-05
Lori Braender CMP
 Compliance Officer 68 18-09-09
Peter Boyd CTO
 Chief Tech/Sci/R&D Officer 58 13-07-31
Carl Kraus CTO
 Chief Tech/Sci/R&D Officer - 23-06-25
A. Schobel CTO
 Chief Tech/Sci/R&D Officer 68 05-11-30
Joseph Crusco PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Timothy Morris BRD
 Director/Board Member 61 22-08-09
Santo Costa CHM
 Chairman 78 15-11-30
Gregory Brown BRD
 Director/Board Member 70 07-02-28
A. Schobel CTO
 Chief Tech/Sci/R&D Officer 68 05-11-30
John S. Cochran BRD
 Director/Board Member 58 03-12-31
Marco Taglietti BRD
 Director/Board Member 64 21-02-09
Daniel Barber CEO
 Chief Executive Officer 48 07-06-30
Julie Krop BRD
 Director/Board Member 57 21-02-09

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 85,759,553 81,472,948 ( 95.00 %) 0 95.00 %

Shareholders

NameEquities%Valuation
Bratton Capital Management LP
10.90 %
9,810,958 10.90 % 42 M $
Venrock Associates
6.175 %
5,555,555 6.175 % 24 M $
Armistice Capital LLC
4.362 %
3,924,000 4.362 % 17 M $
Vanguard Global Advisers LLC
2.100 %
1,889,053 2.100 % 8 M $
Renaissance Technologies LLC
1.413 %
1,271,500 1.413 % 5 M $
A. Schobel
1.094 %
984,476 1.094 % 4 M $
Essex Investment Management Co. LLC
0.9405 %
846,167 0.9405 % 4 M $
Daniel Barber
0.9396 %
845,364 0.9396 % 4 M $
Keith Kendall
0.7082 %
637,149 0.7082 % 3 M $
Vahanian & Associates Financial Planning, Inc.
0.6576 %
591,608 0.6576 % 3 M $

Company contact information

Aquestive Therapeutics, Inc.

30 Technology Drive

07059, Warren

+

http://www.aquestive.com
address Aquestive Therapeutics, Inc.(AQST)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for Aquestive Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.07 USD
Average target price
9 USD
Spread / Average Target
+121.13%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
AQUESTIVE THERAPEUTICS, INC. Stock Aquestive Therapeutics, Inc.
+101.49% 368M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. AQST Stock
  4. Company Aquestive Therapeutics, Inc.